This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

R&D value measurement

Is R&D earning its investment?




Deloitte and Thomson Reuters have collaborated in this study of R&D value measurement, combining Deloitte’s R&D advisory experience and financial expertise with Thomson Reuters R&D data and business insights. Please download the full paper to learn more about how Pharmaceutical innovation is facing a fundamental productivity challenge

Key findings

“Is R&D earning its investment?” has generated the following key points:

  • An R&D investment model based on ‘percentage of sales revenue’ is no longer fit for purpose against a backdrop of declining R&D productivity.
  • The complexity of the R&D business model has outgrown the capabilities of portfolio or value based management techniques to guide business decision making.
  • Deloitte and Thomson Reuters ‘whole R&D business’ assessment of R&D returns indicates that the 12 largest pharmaceutical companies (by R&D spend) are each achieving a positive return (IRR) relative to the group’s average WACC.
  • We have developed a case company IRR simulation to quantify the impact of key change drivers on R&D returns. Our value modelling pinpoints improvements in product differentiation and cost efficiency as having the greatest impact on IRR performance.


Share this page

Email this Send to LinkedIn Send to Facebook Tweet this More sharing options

Get in touch

More on Deloitte